Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome

Fuente: FierceBiotech
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
Volver